Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · IEX Real-Time Price · USD
1.270
+0.050 (4.10%)
Jul 22, 2024, 10:15 AM EDT - Market open
Company Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States.
It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Iterum Therapeutics plc
| Country | Ireland |
| Founded | 2015 |
| IPO Date | May 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Corey N. Fishman |
Contact Details
Address: Fitzwilliam Court, 1st Floor, Leeson Close Dublin 2, L2 D02 YW24 Ireland | |
| Phone | (872) 225-6077 |
| Website | iterumtx.com |
Stock Details
| Ticker Symbol | ITRM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001659323 |
| CUSIP Number | G6333L101 |
| ISIN Number | IE000TTOOBX0 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Corey N. Fishman | President, Chief Executive Officer and Director |
| Judith M. Matthews | Chief Financial Officer |
| Dr. Michael W. Dunne M.D. | Strategic Advisor and Director |
| Dr. Sailaja Puttagunta M.D. | Chief Medical Officer |
| Tom Loughman Ph.D. | Senior Vice President of Technical Operations |
| Louise Barrett | Senior Vice President of Legal Affairs and Secretary |
| Dr. Steven I. Aronin M.D. | Senior Vice President and Head of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 22, 2024 | 8-K | Current Report |
| Jul 19, 2024 | EFFECT | Notice of Effectiveness |
| Jul 19, 2024 | 424B3 | Prospectus |
| Jul 17, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 26, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 26, 2024 | 8-K | Current Report |
| Jun 21, 2024 | 8-K | Current Report |
| Jun 7, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 31, 2024 | 8-K | Current Report |
| May 13, 2024 | 10-Q | Quarterly Report |